drugset / Trial / NCT01756339

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01756339

Phase 3 Completed 860 enrolled Melinta Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.

Timeline

Start
2012-12
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Solithromycin Other / unclassified 400 mg Oral

Indications